Galera Therapeutics, Inc. (GRTX)의 가격은 얼마입니까?

Galera Therapeutics, Inc. (GRTX)의 가격은 $17.15입니다.

Galera Therapeutics, Inc. (GRTX)의 시가 총액은 무엇입니까?

Galera Therapeutics, Inc. (GRTX)의 시가 총액은 $6.51M입니다.

Galera Therapeutics, Inc. (GRTX) 영업이익률

Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation and commercialization of therapies aimed at revolutionizing cancer radiotherapy. Its lead investigational drug, avasopasem manganese (GC4419), functions as a small molecule superoxide dismutase mimetic. This compound has successfully completed a Phase III clinical trial targeting severe oral mucositis induced by radiation therapy in head and neck cancer (HNC) patients. Furthermore, GC4419 is currently undergoing Phase IIa clinical trials for radiotherapy-induced esophagitis in lung cancer patients, as well as for HNC patients undergoing standard-of-care radiation treatment. The company is also progressing with GC4711, another superoxide dismutase mimetic candidate, which is in a Phase I/II clinical trial. This trial evaluates its combination with stereotactic body radiation therapy (SBRT) for individuals diagnosed with non-small cell lung cancer and locally advanced pancreatic cancer. Galera Therapeutics was founded in 2012 and maintains its headquarters in Malvern, Pennsylvania.

연도	영업이익률	변화
2026 (TTM)	0.00%	0.00%
2024	0.00%	0.00%
2023	0.00%	0.00%
2022	0.00%	0.00%
2021	0.00%	0.00%
2020	0.00%	0.00%
2019	0.00%	0.00%
2018	0.00%	0.00%
2017	0.00%	0.00%

연도

영업이익률

변화

2026 (TTM)

0.00%

2024

0.00%

2023

0.00%

2022

0.00%

2021

0.00%

2020

0.00%

2019

0.00%

2018

0.00%

2017

0.00%

회사	영업이익률	영업이익률 차이	국가
Vertex Pharmaceuticals Incorporated VRTX.US	38.97%	-	US
Argenx SE ARGX.US	28.81%	-	NL
Lonza Group AG LONN.SW	0.00%	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	0.00%	-	KR
UCB S.A. UCB.BR	31.23%	-	BE

회사

영업이익률

영업이익률 차이

국가